Literature DB >> 22083616

Anti-cyclic citrullinated peptide antibodies and rheumatoid factor sera titers in leprosy patients from Mexico.

María G Zavala-Cerna1, Mary Fafutis-Morris, Cecilia Guillen-Vargas, Mario Salazar-Páramo, Diana E García-Cruz, Carlos Riebeling, Arnulfo Nava.   

Abstract

Leprosy offers a broad spectrum of altered immunological sceneries, ranging from strong cell-mediated immune responses seen in tuberculoid leprosy (TT), through borderline leprosy (BB), to the virtual absence of T cell responses characteristic in lepromatous leprosy (LL). The exact mechanism of autoantibodies production remains unknown in leprosy and other chronic inflammatory diseases and also the contribution of these antibodies to the pathogenesis of the disease. The aim of this study is to evaluate the frequency and profiles of serum anti-cyclic citrullinated peptide antibodies (a-CCP), rheumatoid factor (RF) and its relationship with leprosy spectrum. Serum samples from 67 leprosy patients (54 LL, 5 TT and 8 BB) and 46 clinically healthy subjects (CHS) from the same endemic region were investigated. The clinical chart and questionnaire were used to obtain clinical information. Anti-cyclic citrullinated peptide antibodies (a-CCP) were measured by enzyme-linked immunosorbent assay, whereas the rheumatoid factor (RF) levels were measured by nephelometric method. The mean age of patients was 51.5 ± 13 years. Sera levels of a-CCP where higher in leprosy patients than in CHS (5.9 ± 11.6 vs. 0.3 ± 0.29) (P < 0.0001); the same pattern was found for RF sera titers without reaching statistical significance (16.8 ± 22.5 vs. 9.9 ± 3) (P = NS). We did not find a correlation between a-CCP and RF Rho =0.02786 (IC 95%) P = 0.8229. However, LL patients had higher a-CCP and RF levels than TT patients. Although an absence in correlation was observed, the serum levels of a-CCP antibodies and RF appeared to be useful in distinguishing LL from TT patients with a limited significance in detecting reactional leprosy patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22083616     DOI: 10.1007/s00296-011-2224-0

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  32 in total

1.  BASIC PRINCIPLES IN CARRYING OUT A PILOT THERAPEUTIC TRIAL IN LEPROSY.

Authors:  W H JOPLING
Journal:  Lepr Rev       Date:  1965-04       Impact factor: 0.537

2.  Classifying leprosy patients--searching for the perfect solution?

Authors:  Diana N J Lockwood; Euzenir Sarno; W Cairns Smith
Journal:  Lepr Rev       Date:  2007-12       Impact factor: 0.537

Review 3.  Rheumatoid factors in leprosy and parasitic diseases.

Authors:  M Harboe
Journal:  Scand J Rheumatol Suppl       Date:  1988

Review 4.  T cell unresponsiveness in lepromatous leprosy.

Authors:  T Kamradt
Journal:  J Rheumatol       Date:  1993-05       Impact factor: 4.666

5.  T lymphocyte subsets in the skin lesions of patients with leprosy.

Authors:  R L Modlin; F M Hofman; C R Taylor; T H Rea
Journal:  J Am Acad Dermatol       Date:  1983-02       Impact factor: 11.527

6.  Anti-neutrophil cytoplasmic antibodies in leprosy.

Authors:  Fernando Luiz Barros Edington; Maria Olívia Amado Ramos Bacellar; Paulo Roberto Machado; Lúcio Barbosa; Eliana Reis; Mitermayer Reis; Mittermayer Barreto Santiago
Journal:  Clin Rheumatol       Date:  2006-03-30       Impact factor: 2.980

7.  Cutting edge: a Toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling.

Authors:  Pierre-Yves Bochud; Thomas R Hawn; Alan Aderem
Journal:  J Immunol       Date:  2003-04-01       Impact factor: 5.422

Review 8.  Autoimmune phenomena in leprosy, particularly antinuclear antibodies and rheumatoid factor.

Authors:  I Garcia-De La Torre
Journal:  J Rheumatol       Date:  1993-05       Impact factor: 4.666

9.  Anti-cyclic citrullinated peptide antibodies and rheumatoid factor in leprosy patients with articular involvement.

Authors:  S L E Ribeiro; H L A Pereira; N P Silva; R M S Neves; E I Sato
Journal:  Braz J Med Biol Res       Date:  2008-11       Impact factor: 2.590

10.  Circulating cytokine profiles in leprosy patients.

Authors:  Vasudha A Belgaumkar; Neeta R Gokhale; Pradeep M Mahajan; Renu Bharadwaj; Dakshayani P Pandit; Shantanu Deshpande
Journal:  Lepr Rev       Date:  2007-09       Impact factor: 0.537

View more
  4 in total

1.  Hansen's Disease and Rheumatoid Arthritis Crossover of Clinical Symptoms: A Case Series of 18 Patients in the United States.

Authors:  Sarah M Labuda; John S Schieffelin; Jeffrey G Shaffer; Barbara M Stryjewska
Journal:  Am J Trop Med Hyg       Date:  2017-10-19       Impact factor: 2.345

Review 2.  Lucio's phenomenon: report of five cases.

Authors:  Pablo Finucci Curi; Julieta Solis Villaroel; Nora Migliore; Adriana Albertengo; María Laura Aquino; Federico Ceccato; Sergio Paira
Journal:  Clin Rheumatol       Date:  2014-05-27       Impact factor: 2.980

3.  Rheumatoid arthritis-like features in Hansen disease: A case report.

Authors:  Le-Nyu Gao; Bing Zhong; Yong Wang
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

4.  Case for diagnosis. Infiltrated areas on the trunk.

Authors:  Larissa Daniele Machado Góes; Juliana Alves Scrignoli; Patrícia Morais; Carolina Talhari
Journal:  An Bras Dermatol       Date:  2020-06-25       Impact factor: 1.896

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.